reports
Net Asset Value(s)
Net Asset Value(s) WisdomTree Issuer plc – Daily Fund Prices 25-April-24 WisdomTree Artificial Intelligence UCITS ETF - USD Acc24/04/2024IE00BDVPNG1314054630USD845,390,073.4960.1503WisdomTree AT1 CoCo Bond UCITS ETF - EUR Hedged24/04/2024IE00BFNNN2361662036EUR135,999,021.0681.8268WisdomTree Artificial Intelligence UCITS ETF - USD Acc25/04/2024IE00BDVPNG1314054630USD840,758,011.8659.8207WisdomTree AT1 CoCo Bond UCITS ETF - EUR Hedged25/04/2024IE00BFNNN2361662036EUR135,740,932.7481.6715WisdomTree AT1 CoCo Bond UCITS ETF - GBP Hedged25/04/2024IE00BFNNN459171509GBP14,665...
Forløb af ekstraordinær generalforsamling fredag den 26. april 2024
Forløb af ekstraordinær generalforsamling fredag den 26. april 2024 SELSKABSMEDDELELSE A.P. Møller - Mærsk A/S – Forløb af ekstraordinær generalforsamling fredag den 26. april 2024 Den ekstraordinære generalforsamling i A.P. Møller - Mærsk A/S afholdtes fredag den 26. april 2024 som fuldstændig elektronisk generalforsamling i henhold til nedenstående dagsorden. Bestyrelsen havde udpeget advokat Niels Kornerup til dirigent. Dagsorden Gennemførsel af s...
Development of the Extraordinary General Meeting on Friday 26 April 20...
Development of the Extraordinary General Meeting on Friday 26 April 2024 ANNOUNCEMENT A.P. Møller - Mærsk A/S - Development of the Extraordinary General Meeting on Friday 26 April 2024 The Extraordinary General Meeting of A.P. Møller - Mærsk A/S took place on Friday 26 April 2024 as a completely electronic general meeting in accordance with the below agenda. The Board of Directors had appointed Niels Kornerup, attorney-at-law, as chair of the meeting. Agenda Completion of the demerger. The Genera...
- Emily Liu
Hybridan Research : Roquefort Therapeutics : Licensing deals and/or ot...
Roquefort Therapeutics today announced its audited results for the year ended 31 December 2023. The net loss was £1.7m (2022: loss of £1.6m) due to ongoing R&D and administrative expenses. As at 31 December 2023, the cash position was £0.5m (2022: £2.3m). Management aims to prepare at least one program for a Phase 1 clinical study. It is likely Roquefort will need to raise further funds (either through licencing deals and/or other financing arrangements) to complete existing pre-clinical develop...
- Bert Colijn
Eurozone bank lending continues to cautiously recover
The European Central Bank is on the verge of starting rate cuts and monetary developments are proving no hurdle to doing so. March data shows a subdued recovery in bank lending and money growth. With inflation expectations falling further, today's data is in line with a start to cautious rate cuts
- Martin Marandon-Carlhian
- Stephane Houri
ams OSRAM : Q1 2024 results in line, Q2 guidance below expectations, i...
>Q1 2024 results globally in line with expectations but above on FCF - This morning, ams OSRAM reported its Q1 2024 results which were globally in line with expectations. Revenues were € 847m, in line with the Visible Alpha consensus at € 845m. They were down 7% q-o-q and down 9% y-o-y but up 5% y-o-y on a like-for-like basis. The main drivers for this year-on-year increase are the automotive (+13% y-o-y) and consumer (+15% y-o-y) semiconductor businesses, whilst indu...
- Fatma Agnès Hamdani
Savencia SA : Q1 weaker than expected. Flat organic growth
>Q1 sales of € 1,696m up 1.6% and flat on an organic basis at +0.1%. Organic growth is adjusted for the hyperinflation situation in Argentina - Q1 sales rose slightly by 1.6% to € 1,696m. This is well below our estimate of € 1,832.1m. Organic growth was flat at 0.1% vs 11.5% expected. The growth differential concerns in particular other dairy products. The division reported sales of € 762m, up 2.1% and down -2.1% in organic terms (vs +23.2% in Q1 and +23.8% in Q4 2023...
- Gerardo Ibanez
- Steven Boumans
Cofinimmo : Q1 2024 results: Inline results, with a reiterated outlook...
>Outlook reiterated, inline results, underlying metrics look good - Outlook FY2024 Net result from core activities reiterated at €6.40 and €6.20 DPS.Like-for-like devaluations of -€46m or -0.7% (FY 2023: -2.7%).Healthcare operator performance is improving, with underlying occupancy being strong at >90% for all countries with the exception of Germany (84%) from the data collected.Gross rental income up +2.2% on a like-for-like basis (vs FY2023: +5.5% and...
- Wim Gille
Signify : Weak first quarter, but momentum picking up.
>A weak first quarter - The company is in the process of restructuring its internal business lines / reporting and hence we only have results on group level and limited disclosure on business unit level for this quarter as previously announced. Group revenues fell 4,9% short of expectations as the comparable sales growth (CSG) came in at minus 10,1% vs minus 7,3% expected. On a sequential basis CSG in Professional deteriorated from -2,9% in 4Q23 to -7,6% in 1Q24, larg...
- Florent Laroche-Joubert
Gecina : Very good topline performance, with improved visibility on fu...
>Solid operating performance, with organic growth remaining strong at 6.2% - Gecina delivered a solid operating performance in Q1 2024, in line with 2023, with gross rental income of € 173.8m (€ 170.9m), up 4.3% as reported and 6.2% on a like-for-like basis, driven in particular by indexation of +5.2% yoy, the effects of a generally stable occupancy rate over the quarter (contribution -0.2%) and the positive impact of reversion in both offices and residential properti...
- Martijn Den Drijver
Umicore : Cautious tone Battery Materials but 2024 EBITDA guidance mai...
>Reiterating 2024 EBITDA guidance of €900-€950m - Umicore has published a 1 page qualitative trading update about Q1 2024 in which it reiterated EBITDA guidance for 2024 (€900-€950m) so in that sense there are little surprises. Consensus is at €932m and we are at €909m. No analyst call is planned.Catalysis and Recycling performing in line with expectations - Umicore states that Catalysis is making headway on costs and efficiency gains (also in WC) whi...
- Nicolas David
TietoEVRY : Lower than expected Q1 2024 results but full-year guidance...
>Lower than expected organic growth and EBITA. Disappointing FCF - Tietoevry reported its Q1 2024 results yesterday before market opening. Organic growth was -2.0% year-on-year (vs. ODDO BHF estimate of -0.2%), which represents a slowdown relative to 1% in Q4. Growth was impacted by a poor performance in 1/ Tech Services (organic growth of -7% vs. ODDO BHF estimate of -4.8%); 2/ Create (organic growth of -5% vs. ODDO BHF estimate of -0.7%), due to the ongoing weak eco...
- Louis Boujard
- CFA
- Philippe Ourpatian
Voltalia : Instructive exchanges at the virtual road show
>Neutral rating and target price of € 7.70 maintained - Following the publication of the Q1 revenues, we organised a virtual road show for European investors, excluding France. CFO Sylvine Bouan, Head of Marketing and Communications Loan Duong and Head of Investor Relations Armel Ahidazan were present. This discussion with investors essentially centred on a Q&A session. The group obviously confirmed its 2024 and 2027 trajectory but above all provided insights into inv...
- Robert Jan Vos
Basic-Fit N.V. : Memberships and clubs fine; sales 2% shy; guidance in...
>On most key headlines, Basic-Fit reported in-line Q1 2024 results - Basic-Fit reported 4.05m memberships, 1,506 clubs and revenue of € 284m in Q1 2024. We had forecasts 4.055m memberships, 1,510 clubs and € 290m in revenue (there is no reliable consensus available). The average monthly revenue per membership amounted to € 23.57, which was a tad lower than our forecast of € 23.67. The number of clubs were as expected in France (814) and in Spain (199), a tad below our...
Aktietilbagekøbsprogram
Aktietilbagekøbsprogram Nørresundby, 26. april 2024Meddelelse nr. 23/2024 Bestyrelsen i RTX har, jf. selskabsmeddelelse nr. 20/2023 af 30. november 2023, besluttet at iværksætte et aktietilbagekøbsprogram i overensstemmelse med bestemmelserne i artikel 5 i Europa-Parlamentets og Rådets forordning (EU) nr. 596/2014 af 16. april 2014 (MAR) og Kommissionens delegerede forordning (EU) 2016/1052, også kaldet "Safe Harbor"-forordningen. Under programmet vil RTX tilbagekøbe aktier for et beløb på op til DKK 20 mio. i perioden fra 1. december 2023 til 30. september 2024. Følgende transaktioner e...
Share repurchase programme
Share repurchase programme Nørresundby, 26 April 2024Announcement no. 23/2024 The Board of Directors of RTX has, cf. company announcement no. 20/2023 dated 30 November 2023, resolved to initiate a share buy-back programme in accordance with the provisions of Article 5 Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 (MAR) and the Commission’s delegated Regulation (EU) 2016/1052, also referred to as the "Safe Harbor" regulation. Under the programme RTX will buy back shares for an amount up to DKK 20 million in the period from 1 December 20...
Relx: 1 director
A director at Relx bought 1,630 shares at 3,229p and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Clos...
BRP Inc: 1 director
A director at BRP Inc sold after exercising options 87,400 shares at 95.748CAD and the significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last ...
- Oliver Metzger
STRATEC SE : Q1 review – Weak start to the year due to higher destocki...
>Top line with positive momentum, but below expectations - Stratec’s Q1 2024 revenues of € 50.9m (-17.2% y-o-y) was impacted by a -15.7% decline at constant currencies), which were -17%/-18% below our and the consensus’ expectations. The consolidation of Natech Plastics contributed around 470bp to revenues growth. The first quarter was impacted by destocking as guided before, but the headwind was more severe than expected. Bottom line with sequential grow...
- Christophe-Raphaël Ganet
Guerbet : Q1 2024 revenue: a solid sales performance
>Q1 2024 revenue +8%: solid - Revenue increased by 8.1% in Q1 to € 194.3m (+8.8% cc.) or +7.6% after adjusting the first quarter of 2023 to include Intrasense consolidated since 01/01/2023. The EMEA region posted a decline of 5.8% (-6.2% cc), APAC delivered 20% growth (+26.8% cc) and the Americas recorded 21% growth (+20% cc). The X-ray business turned in +15%, the IRM business -4% and the II business +4.4%.Management confirmed its guidance targets (8% growt...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.